Neutralizing/Blocking

Neutralizing antibodies bind to key antigenic sites of viral or bacterial exotoxins, inhibiting their infectivity by blocking their entry into target cells. For viruses, these antibodies recognize and bind to epitopes involved in cellular entry, effectively halting infection. Against bacterial exotoxins, neutralizing antibodies typically target the B subunit, preventing toxins from reaching target cells and protecting the host. Blocking antibodies, on the other hand, bind directly to target proteins, disrupting receptor interactions or protein activity. These antibodies play a critical role in biological research, vaccine development, and therapeutic antibody creation.

AtaGenix provides advanced antibody discovery technologies, including Single B rabbit monoclonal antibody development, mouse hybridoma technology, and phage display library screening, offering tailored solutions for cutting-edge research and drug development.

Contact Us